Latest news with #GLOBOCAN
Time of India
3 days ago
- Health
- Time of India
World No Tobacco Day observed in city
Ranchi: Sadar hospital and the department of community medicine and Tobacco Cessation Centre at Rajendra Institute of Medical Sciences on Saturday held awareness programs to mark the World No Tobacco Day. Tired of too many ads? go ad free now The theme, "Bright Products, Dark Intention: Unmasking the Appeal", shed light on the deceptive marketing practices of the tobacco industry and severe health hazards caused by tobacco use. Civil surgeon Dr Prabhat Kumar, said, "Around 1,15,000 people die each month in India due to tobacco use. We urge individuals to seek help from Sadar's Tobacco Cessation Centre. " Rims director, Raj Kumar, citing GLOBOCAN 2012, stated, "Out of 150 cancer cases per 1 lakh people, 35 are directly linked to tobacco use, including lung, oral, tongue, bladder, and pancreatic cancers." Ranchi: Sadar hospital and the department of community medicine and Tobacco Cessation Centre at Rajendra Institute of Medical Sciences on Saturday held awareness programs to mark the World No Tobacco Day. The theme, "Bright Products, Dark Intention: Unmasking the Appeal", shed light on the deceptive marketing practices of the tobacco industry and severe health hazards caused by tobacco use. Civil surgeon Dr Prabhat Kumar, said, "Around 1,15,000 people die each month in India due to tobacco use. We urge individuals to seek help from Sadar's Tobacco Cessation Centre. " Rims director, Raj Kumar, citing GLOBOCAN 2012, stated, "Out of 150 cancer cases per 1 lakh people, 35 are directly linked to tobacco use, including lung, oral, tongue, bladder, and pancreatic cancers."
Fashion Value Chain
22-05-2025
- Health
- Fashion Value Chain
Metropolis Healthcare Launches TruHealth Cancer Screen 360, a First-of-its-kind Initiative to Strengthen Preventive Oncology in India
As cancer continues to pose a growing public health concern, Ameera Shah-led Metropolis Healthcare Limited, India's second-largest and most respected diagnostic laboratory chain, has announced the launch of TruHealth Cancer Screen 360-a comprehensive screening panel aimed at revolutionizing Preventive Oncology in India. A first-of-its-kind in the Indian diagnostics space, the TruHealth Cancer Screen 360 Male and Female Profiles are scientifically curated to provide early insights, equipping both clinicians and individuals with critical, actionable information. This launch reinforces Metropolis' commitment to enhancing access to specialized cancer diagnostics while making them more affordable and inclusive. Metropolis Healthcare Launches TruHealth Cancer Screen 360, a First-of-its-kind Initiative to Strengthen Preventive Oncology in India According to the Global Cancer Observatory (GLOBOCAN) 2022, cancer remains a major global health concern. In the South-East Asia region, India ranks third in terms of cancer incidence, second for mortality, and 121st in terms of crude rates globally. Alarmingly, screening coverage in India-especially among women-remains under 1% for cervical, breast, and oral cancers, far below the World Health Organizations 70% target for cervical cancer screening. Limited access to healthcare, low awareness, and financial constraints continue to hinder the adoption of widespread screening. The TruHealth Cancer Screen 360 includes tumor markers, hereditary cancer risk analysis, and gender-specific screening modules-such as PSA for prostate cancer in men and HPV self-sampling for cervical cancer in women. Designed to address the rising cancer burden and bridge diagnostic gaps, the panel offers a multi-layered, evidence-based approach to detect early signs of common cancers in both men and women. Commenting on the launch, Mr. Surendran Chemmenkottil, CEO, Metropolis Healthcare Ltd., said, 'The introduction of TruHealth Cancer Screen 360 Male and Female Profiles reflects our unwavering commitment to strengthening preventive healthcare in India. By equipping individuals with timely and reliable diagnostic tools, we aim to empower them to take charge of their health. Early detection is key to reducing the burden of late-stage cancer, improving outcomes, and saving lives. This initiative is also aligned with our strategic focus on expanding Metropolis' footprint in oncology diagnostics-an increasingly critical domain in healthcare. We remain committed to making advanced diagnostics accessible and affordable across both urban and non-urban areas.' A recent GLOBOCAN report also highlights a concerning trend-earlier onset of cancers in urban populations, with rising incidence of breast, cervical, and ovarian cancers in women, and lung and prostate cancers in men. These often go undiagnosed until advanced stages, making treatment more difficult and outcomes less favourable. Dr. Kirti Chadha, Senior Oncopathologist and Chief Scientific and Innovation Officer, Metropolis Healthcare Ltd. said, 'With the growing incidence of gender-specific cancers such as breast, cervical, and prostate, there is an urgent need to integrate targeted cancer screening into routine health check-ups. The TruHealth Cancer Screen 360 has been developed as an evidence-based, comprehensive tool that goes beyond general wellness testing. By incorporating a broad spectrum of biomarkers and hereditary risk indicators, it facilitates early identification of cancer risks-even before symptoms appear. This approach enhances clinical decision-making and provides individuals with actionable insights, helping bridge the gap between symptomless disease progression and timely medical intervention.' Key features of TruHealth Cancer Screen 360 (Male & Female Profiles) Gender-specific panels for breast, ovarian, cervical, liver, lung, prostate, colorectal, and thyroid cancers. Three-layered screening combining tumor markers, hereditary cancer risk analysis (covering 25+ cancer types), and organ-specific assessments. Hereditary cancer screening through a NextGen Panel that analyses 317 genes, enabling preventive measures for patients and family members. HPV Self-Sampling (Female Profile): WHO-recommended self-test kits for primary cervical cancer screening-removing barriers like discomfort, time constraints, or clinic access. Free genetic counseling with certified counsellors to support individuals in understanding results and next steps. The TruHealth Cancer Screen 360 is available at an introductory price, significantly lower than the combined cost of individual tests-making this advanced screening solution both affordable and accessible. With a robust portfolio of over 4,000 tests and profiles, Metropolis continues to lead diagnostic innovation. Through this integrated cancer screening initiative, the company reaffirms its mission to drive early diagnosis, clinical excellence, and preventive healthcare for all. About Metropolis Healthcare Limited Established in 1981, Metropolis Healthcare Limited is India's second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company's extensive footprint spans 22 states, 3 Union Territories, and over 750 towns in India, supported by a robust network of more than 210 laboratories, 4,500 patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company's commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 98% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit or click on Twitter, Facebook, or LinkedIn.
Yahoo
19-05-2025
- Health
- Yahoo
$10+ Bn Artificial Intelligence (AI) in Precision Medicine Market Insights, Competitive Landscape, and Forecasts 2024-2025 & 2032
The Artificial Intelligence (AI) in Precision Medicine Market is projected to expand at a CAGR of 33.18% from 2025 to 2032, driven by rising chronic and genetic diseases. Covering key technologies like deep learning and machine learning, the market is set to reach USD 10.24 billion by 2032, propelled by AI advancements in diagnostics, drug development, and personalized healthcare across major regions. Dublin, May 19, 2025 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Precision Medicine - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been added to offering. The Artificial Intelligence (AI) in precision medicine market is poised for robust growth, propelled by the urgent need for personalized treatment amidst the global rise in chronic and genetic diseases. The market, valued at USD 1.03 billion in 2024, is projected to grow at a CAGR of 33.18%, reaching USD 10.24 billion by 2032. The increasing complexities in disease diagnosis and treatment have heightened the demand for AI-powered precision diagnostics and therapeutics, which are instrumental in analyzing complex biological data. Technological advancements and innovative product development enhance the precision and speed of medical interventions. Strategic product launches by industry leaders, backed by vigorous research and development (R&D) activities, accelerate market growth, setting a promising trajectory for the forecast period (2025-2032). However, challenges such as data privacy concerns, regulatory hurdles, and the need for clinical validation could impede rapid expansion. According to GLOBOCAN data, cancer cases are expected to skyrocket from 20 million in 2022 to 35 million by 2050, indicating a significant demand for AI-powered solutions in oncology. The Breast Cancer Research Foundation reports 2.3 million breast cancer cases in 2022, while lung and colorectal cancers accounted for 2.48 million and 1.93 million cases, respectively, the same year. These alarming statistics underscore the need for precision medicine in cancer care. The World Health Organization and the International Diabetes Federation highlight a surge in cases of cardiovascular diseases, diabetes, and viral infections, necessitating more targeted and proactive healthcare solutions. AI technologies facilitate early diagnosis, personalized treatment plans, and real-time monitoring, paving the way for data-driven, individualized care. The latest data from the Personalized Medicine Coalition indicates an upward trend in FDA-approved personalized treatments, with 16 new approvals in 2023, reinforcing the emphasis on individualized care. Notably, Tempus AI, Inc.'s FDA clearance for its AI-powered Tempus ECG-AF exemplifies the sector's innovation, aiding early detection of atrial fibrillation. Regionally, North America is projected to dominate the market, driven by advanced R&D, a well-established healthcare infrastructure, and increasing chronic and lifestyle diseases. Market leaders like Prenosis and Ibex Medical Analytics continue to push boundaries with novel AI-driven diagnostic tools. For instance, Prenosis's Sepsis ImmunoScoreT and Ibex's Prostate Detect leverage AI for improved diagnosis and patient care. Leading players like TEMPUS, GE HealthCare, and others are key contributors to the market's development. Partnerships, such as Illumina Inc. and Tempus AI, align towards accelerating genomic testing, while FDA-approved triage tools for detecting fractures exemplify the strides being made in AI applications in medicine. In conclusion, the Artificial Intelligence in precision medicine market is set for substantial expansion by 2032, supported by technological innovations and an increasing focus on personalized healthcare solutions. Leveraging AI's analytical power, the industry is transforming healthcare delivery, ensuring faster diagnoses and tailored treatments, aligning with global health needs. Key Topics Covered: 1. Artificial Intelligence (AI) in Precision Medicine Market Report Introduction 1.1. Scope of the Study 1.2. Market Segmentation 1.3. Market Assumption 1.4. Project Approach 2. Artificial Intelligence (AI) in Precision Medicine Market Executive Summary 2.1. Market at Glance 3. Competitive Landscape 4. Regulatory Analysis 5. Artificial Intelligence (AI) in Precision Medicine Market Key Factors Analysis 5.1. Artificial Intelligence (AI) in Precision Medicine Market Drivers 5.2. Artificial Intelligence (AI) in Precision Medicine Market Restraints and Challenges 5.3. Artificial Intelligence (AI) in Precision Medicine Market Opportunities 6. Artificial Intelligence (AI) in Precision Medicine Market Porter's Five Forces Analysis 6.1. Bargaining Power of Suppliers 6.2. Bargaining Power of Consumers 6.3. Threat of New Entrants 6.4. Threat of Substitutes 6.5. Competitive Rivalry 7. Artificial Intelligence (AI) in Precision Medicine Market Assessment 7.1. By Product 7.2. By Technology 7.3. By Application 7.4. By Therapeutic Area 7.5. By Geography 8. Artificial Intelligence (AI) in Precision Medicine Market Company and Product Profiles 8.1. TEMPUS 8.2. GE HealthCare 8.3. 8.4. Envisionit Deep AI (Pty) Ltd. 8.5. 8.6. Aignostics, Inc. 8.7. Proscia Inc. 8.8. Ultivue, Inc. 8.9. Prenosis, Inc. 8.10. IBEX 8.11. Cleerly, Inc. 8.12. Paige AI, Inc. 8.13. Densitas 8.14. Photocure ASACo. 8.15. iCAD, Inc. 8.16. Eko Health, Inc. 8.17. Owkin, Inc. 8.18. Massive Bio 8.19. Deep Bio Inc., Inc. 8.20. Atomwise Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Time of India
08-05-2025
- Health
- Time of India
World Ovarian Cancer Day 2025: Know the signs and symptoms
Ovarian cancer is one of the most lethal cancer affecting females. According to GLOBOCAN 2020 statistics, 1.6% of new cases and 2.1% of deaths of all sites are attributable to ovarian cancer. It is the fourth most common cancer in Indian women with an incidence of 4.9 cases per 100,000. The crude mortality rate and age-standardized mortality rate of ovarian cancer are 2.3 and 2.02 per 100,000, respectively. In about 90% cases, ovarian cancer is a sporadic event, and in only 5 to 10% cases there is a hereditary genetic mutation, especially in BRCA genes. Since the symptoms are often vague and non-specific, majority of the patients are diagnosed in advanced stage (70%-80%), with poor long-term survival (15%-30%), compared with those with early-stage disease, where survival exceeds 80%. Operation Sindoor 'Op Sindoor's precision & execution was unimaginable': Rajnath Singh Operation Sindoor: India repels drone, missile attack across LoC Operation Sindoor: Several airports in India closed - check full list Major trails done in the past have failed to show any survival benefit with routine screening. • The US Preventive Services Task Force (USPSTF) 2018 recommendation statement continues to recommend against screening for ovarian cancer for asymptomatic women who are not known to have a high-risk hereditary cancer syndrome • Patients identified with a high-risk family history should be referred to a genetic counselor and genetic screening for a possible hereditary cancer syndrome ( BRCA1, BRCA2, Lynch syndrome, and other mutations). Patients who test positive for one of these syndromes may benefit from interventions such as risk-reducing bilateral salpingo-oophorectomy Symptom-triggered testing for ovarian cancer has been endorsed by various cancer organisations like American cancer society and Society of Gynecologic Oncology. Though ovarian cancer was considered a silent killer, some symptoms if of new onset, coexistent with other symptoms, present almost daily for a few weeks and considered severe than expected, should be evaluated and can increase the chances of detecting disease in early stage These include Bloating Abdominal or pelvic pain Difficulty in eating or feeling full quickly Urinary urgency or frequency Symptoms usually precede the diagnosis by between 3 and 36 months Studies have shown that with symptom based testing by CA125 and USG, 25% of high grade serous ovarian cancers can be detected at early stage or in advanced stage with a low volume disease burden more amenable to complete cytoreduction, thus improving the survival. (By Dr. Vandana Jain, Senior Consultant and Head of the Department of Gynecologic Oncology at RGCIRC) Masterclass for Students. Upskill Young Ones Today!– Join Now
News18
08-05-2025
- Health
- News18
How Lifestyle Changes And Early Detection Can Help Prevent Ovarian Cancer
Last Updated: Ovarian cancer is often diagnosed late due to subtle early symptoms and limited screening options, leading to low five-year survival rates. World Ovarian Cancer Day, marked on May 8 every year, highlights a critical women's health issue in India. According to GLOBOCAN 2022 estimates, ovarian cancer ranks third among cancers in Indian women, with 47,333 new cases diagnosed in 2022. Often detected at an advanced stage, early ovarian cancer symptoms are subtle, and a lack of reliable population screening contributes to low five-year survival rates. To reduce its incidence, Dr. Jayasree Kuna, Consultant Radiation Oncologist at Apollo Cancer Centres in Visakhapatnam, explains why it is essential to understand what may cause ovarian cancer and learn how to prevent it through lifestyle adjustments and timely medical care. Embrace a plant-forward eating pattern rich in fruits, vegetables, whole grains and lean proteins, while limiting red and processed meats, sugary drinks and alcohol. These choices help maintain healthy weight and hormone levels, both of which are cancer risk factors. Stay Active and Manage Weight Aim for at least 150–300 minutes of moderate-intensity activity each week, such as brisk walking, cycling or yoga, and incorporate muscle-strengthening exercises twice weekly. Regular physical activity regulates hormones, reduces inflammation and helps prevent excess weight gain, all of which may contribute to a reduced risk of ovarian cancer. Acknowledge Hereditary Factors Persistent bloating, pelvic or abdominal pain, early satiety, urinary urgency and changes in bowel habits can all signal ovarian cancer. Since routine screening tests (CA-125 blood tests and transvaginal ultrasound) are not recommended for average-risk, asymptomatic women, anyone experiencing these ovarian cancer symptoms, especially those at higher genetic risk, should consult a gynaecologist promptly. This can expedite the ovarian cancer diagnosis, which opens up a wider range of ovarian cancer treatment options for better outcomes. By embracing healthy lifestyle habits, staying informed about personal risk factors, and acting swiftly on early symptoms, women across India can take positive, proactive steps to reduce their chances of developing ovarian cancer. First Published: May 08, 2025, 14:12 IST
